Subscribe To
PRVB / Provention Bio's Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months
Content Topics
Provention
Bio
Coxsackievirus
Vaccine
Candidate
Elicits
Durable
Virus neutralizing
Antibodies
Months
Stock
PRVB
PRVB News
By The Motley Fool
March 16, 2023
Why Provention Bio Stock Skyrocketed 256% This Week
Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup. more_horizontal
By Zacks Investment Research
March 14, 2023
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023. more_horizontal
By InvestorPlace
March 13, 2023
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal ha more_horizontal
By PRNewsWire
February 23, 2023
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
RED BANK, N.J. , Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercept more_horizontal
By Seeking Alpha
February 22, 2023
Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry
PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades. more_horizontal
By Zacks Investment Research
February 13, 2023
Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?
Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might more_horizontal
By Zacks Investment Research
February 8, 2023
Here's Why 'Trend' Investors Would Love Betting on Provention Bio, Inc. (PRVB)
Provention Bio, Inc. (PRVB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound more_horizontal
By Seeking Alpha
February 7, 2023
Provention Bio: Ability To Expand T1D Market Presence With Second Half 2023 Data
Received FDA approval of TZIELD for Stage 2 Type 1 Diabetes patients in November of 2022. Potential to increase market potential of TZIELD with ongoin more_horizontal